PDF
(Download)
|
- Ginkgo (Ginkgo biloba, Ginkgoaceae)
- Attention-deficit/Hyperactivity Disorder (ADHD)
- Methylphenidate
|
Date:
07-15-2015 | HC# 061551-524
|
Re: Adjunct Ginkgo Improves Inattention Symptoms in Children with ADHD
Shakibaei
F, Radmanesh M, Salari E, Mahaki B. Ginkgo
biloba in the treatment of attention-deficit/hyperactivity disorder in
children and adolescents. A randomized, placebo-controlled, trial. Complement Ther Clin Pract. May 2015;21(2):61-67.
Attention-deficit/hyperactivity
disorder (ADHD) is characterized by persistent inattention, hyperactivity, and impulsivity.
It is one of the most common neuropsychiatric disorders in children. ADHD is
treated pharmacologically and behaviorally. Approximately 30% of patients with
ADHD do not successfully respond to pharmacological drug treatment, so many seek
herbal treatment. Well-designed, randomized, controlled clinical trials
evaluating herbal treatments for ADHD are lacking. Several open-label studies
indicate that ginkgo (Ginkgo biloba,
Ginkgoaceae) leaf extract is useful for treating ADHD in children. However, a
randomized, controlled study reported that ginkgo was not effective compared
with methylphenidate (Ritalin®; Novartis; Basel, Switzerland).1
The purpose of this randomized, double-blinded, placebo-controlled study was to
evaluate the efficacy of ginkgo as an adjunct therapy to methylphenidate in
children and adolescents with ADHD.
Children
and adolescents (n=66, aged 6-12 years; mean age, 8 years) diagnosed with ADHD according
to the Diagnostic and Statistical Manual
of Mental Disorders (DSM-IV-TR) and referred to the Department of Child and
Adolescent Psychiatry at the Noor University Hospital in Isfahan city, Iran
participated in the study. Included patients had a Children's Global Assessment
Scale (CGAS) score of < 80 indicating decreased general function. Excluded
patients had mental retardation (IQ ≤ 70), type I bipolar disorder, psychosis, pervasive
developmental disorders, organic brain disease, seizure, or cardiovascular
disease. To establish baseline, there was a 2-week run-in where patients were
psychiatric drug-free. Then patients were randomly assigned to receive either methylphenidate
plus ginkgo (Ginko TDTM; TolidDaru Co.; Tehran, Iran) or
methylphenidate plus placebo for 6 weeks. The placebo contained starch and
lactose, and was the same shape and color as the ginkgo preparation. The dose
of methylphenidate was 20 mg/day for patients with body weight of < 30 kg,
and 30 mg/day for those > 30 kg. The methylphenidate dosage was increased 10
mg/week up to the assigned total dose. The ginkgo dose was 80 mg/day for those
with body weight of < 30 kg and 120 mg/day for those > 30 kg. The ginkgo
dosage was increased by 40 mg/week up to the assigned total dose.
The
primary outcome was the amount of change in ADHD Rating Scale-IV (ADHD-RS-IV)
scores after treatment. ADHD-RS-IV is used to assess 18 symptoms of ADHD and includes
2 subscales to assess inattention and hyperactivity/impulsivity; the parent (completed
in interview with clinicians) and teacher form of the instrument was used. Treatment
response was considered a ≥ 27% improvement from baseline in the ADHD-RS-IV
total score. The secondary outcome was a change in global functioning as
assessed by parents in interview with clinicians using the CGAS. The CGAS measures
general (psychosocial) functioning of children. ADHD-RS-IV and CGAS were
measured at baseline and after 2 and 6 weeks of treatment.
Baseline
characteristics were similar between groups. For the ADHD-RS-IV parent rating
after 6 weeks of treatment, the ginkgo group had a significantly greater improvement
in inattention (P=0.001), total score (P=0.001), and clinical response rate
(P=0.002) compared with the placebo group. However, according to the ADHD-RS-IV
teacher rating, the only significant improvement observed was inattention
(P=0.004). Both the parent and teacher ratings showed that ginkgo did not
improve hyperactivity-impulsivity. There was no significant difference between
groups on the CGAS. Side effects were mild, and there were no significant
differences between groups in side effects.
The
authors conclude that adding ginkgo to standard methylphenidate treatment is a
safe and effective adjunct therapy. "Although the additional effect of the herb on ADHD symptoms was actually
minimal and limited to the inattention symptoms, it resulted in a significant
increase in overall clinical treatment response." The mechanism of
action is not clear. Acknowledged limitations of the study were the lack of a
pure placebo arm (it would be unethical to deny treatment), the short study
duration (it is not clear if the benefits would be maintained long-term), and the
lack of patient follow-up after they stopped taking ginkgo (it would be
valuable to see whether the benefit of ginkgo was lost when ginkgo treatment
ended). "Further trials with larger sample size, various drug
dosages, and longer treatment and follow-up duration are warranted."
—Heather S. Oliff,
PhD
Reference
1Salehi B, Imani R, Mohammadi MR, et al. Ginkgo biloba for
attention-deficit/hyperactivity disorder in children and adolescents: a double
blind, randomized controlled trial. Prog
Neuropsychopharmacol Biol Psychiatry. 2010;34(1):76-80.
|